Renin-angiotensin-aldosterone system inhibitors and major cardiovascular events and acute kidney injury in patients with coronary artery disease.

Maneesh K SudDennis T KoAlice ChongMaria KohPaymon M AziziPeter C AustinThérèse A StukelCynthia A Jackevicius

Published in: Pharmacotherapy (2021)

This study supports the continued use of RAASIs in patients with CAD, although the benefit appears smaller in magnitude than observed in prior trials. High-risk patients, particularly those with prior MI, appear to benefit the most from RAASIs.

Keyphrases

cardiovascular events
coronary artery disease
end stage renal disease
ejection fraction
newly diagnosed
angiotensin ii
cardiovascular disease
angiotensin converting enzyme
prognostic factors
type diabetes